Introduction {#sec1}
============

A challenge I, and presumably others who train graduate students, face is getting them to attend departmental seminars. At the start of a new academic year, I often hear complaints from my students about seminars being a distraction from research and that their attending a talk that is not directly aligned with their interests is a poor use of time. In response, I point out that this is an excellent opportunity to learn new things and that seminar attendance is, after all, something I require. I also describe a situation where my attending a seminar, the title of which was not directly aligned with what I thought were my "research interests", had a profound impact on my career.

The lecture^[@ref1]^ was given at the 17th International Carbohydrate Symposium in 1994, the time I was beginning to develop proposals for my applications for independent faculty positions. The speaker was Patrick Brennan of Colorado State University, a pioneer and international leader in determining the structures and biosynthesis of the highly complex carbohydrates (glycans) found in the cell wall of mycobacteria, including the organism that causes tuberculosis, *Mycobacterium tuberculosis*. Brennan is an engaging speaker and the molecules he presented had structures unlike anything I had ever seen. I knew immediately that mycobacterial glycans were something I had to study in my independent career.

The mycobacterial cell wall is a highly complex structure composed largely of carbohydrates and lipids ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref2]−[@ref4]^ The major components are two lipidated polysaccharides, the mycolyl--arabinogalactan (AG) complex and lipoarabinomannan (LAM). The structures ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) of both AG and LAM are characterized by the presence of a large number of sugar residues in the furanose (five-membered) ring form. It was these molecules that so intrigued me in Brennan's talk. AG is composed nearly exclusively of such monosaccharides, galactofuranose (Gal*f*) and arabinofuranose (Ara*f*), while LAM contains both Ara*f* and mannopyranose residues. In 1994, there had been relatively few investigations on the synthesis of furanose-containing glycans. For a basic science perspective, this seemed to be an excellent area in which to build a research program. Moreover, from a practical standpoint I was excited by the possibility of the target molecules being applied to study the biology of an organism that causes a disease of great importance and one for which drug resistance had become (and remains) a problem: tuberculosis.

![Representation of the mycobacterial cell wall with all major classes of glycans shown. LAM, lipoarabinomannan; PGLs, phenolic glycolipids; GPLs, glycopeptidolipids; LOSs, lipooligosaccharides. Reproduced with permission from ref ([@ref5]). Copyright 2015 John Wiley & Sons.](ar-2016-001647_0001){#fig1}

![Composite structures of mycobacterial arabinogalactan (AG) and lipoarabinomannan (LAM).](ar-2016-001647_0002){#fig2}

Synthesis of Arabinofuranosides {#sec1.1}
===============================

In charting a course of action, the initial goal was to develop chemistry that could be used for the synthesis of Ara*f*-containing oligosaccharides, which could then serve as substrates for the glycosyltransferases involved in AG and LAM biosynthesis or as ligands for Ara*f*-binding proteins. An initial challenge in the synthesis of furanosides is to obtain derivatives in the less thermodynamically stable five-membered ring form.^[@ref6]^ There are a number of methods for doing this, each with their pros and cons. For arabinose, we found the most straightforward access was through a classic method: Fischer glycosylation under kinetic control. We adopted and refined a reported method^[@ref7]^ to prepare methyl glycoside **1** in two steps from [d]{.smallcaps}-arabinose ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A). This method is robust enough that it can be reliably done in undergraduate teaching laboratories.^[@ref8]^ We subsequently could convert **1**, in one step, into the corresponding thioglycoside **2**([@ref9]) and then into other glycosyl donors (e.g., **3**--**5**).^[@ref10],[@ref11]^ Early in our investigations, we also developed an alternate approach to the Ara*f* system though ozonolysis of protected glucal derivatives (**6** → **7**, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B).^[@ref12]^ This latter method was useful for the preparation of ^13^C labeled materials (from commercially available ^13^C-labeled [d]{.smallcaps}-glucose), which were of interest for NMR spectroscopic studies. However, it is less convenient than Fischer glycosylation for the preparation of materials on large scale.

![Access to the Arabinofuranose Ring System and Donors (**3**--**5**) for the Synthesis of Arabinofuranose-Containing Glycans](ar-2016-001647_0011){#sch1}

The Ara*f* residues in AG and LAM are found as part of α-(1,2-*trans*) and β-(1,2-*cis*) linkages ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). We assumed that the α-linkages could be straightforwardly assembled from glycosyl donors possessing O-2 acylation, for example, **2**. The acyl groups, through neighboring group participation, would ensure the 1,2-*trans* stereochemistry. Indeed, the use of donors analogous to **2** were used by graduate student Joe Ayers to synthesize α-Ara*f*-containing glycans (e.g., **8** and **9**, [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B), which could then be used as acceptor substrates for mycobacterial arabinosyltransferases.^[@ref13]^

![(A) Structures of the α-Ara*f* and β-Ara*f* ring systems and (B) structures of α-Ara*f*-containing oligosaccharides **8** and **9**.](ar-2016-001647_0003){#fig3}

On the other hand, we anticipated that stereoselective access to the β-Ara*f*-linkages would be more difficult, given their stereochemical similarity to β-mannopyranosides. The stereochemistry of these 1,2-*cis*-β systems is such that one can rely on neither neighboring group participation nor thermodynamics (through the anomeric effect) to give the desired product.^[@ref14]^ That said, we did explore the possibility that 2-*O*-benzylated donors (e.g., **3**, **4**) could be used to access β-Ara*f* linkages. We discovered that by carefully controlling the reaction conditions, some donor and acceptor pairs could be coupled with good to excellent β-selectivity.^[@ref10]^ Using this approach a postdoctoral fellow, Haifeng Yin, could synthesize a panel of mycobacterial arabinofuranoside fragments, including the common Ara6 motif (**10**, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), which is found at the nonreducing terminus of both AG and LAM.^[@ref11]^ Subsequent work from the Kim group showed similar results with another class of glycosyl donors.^[@ref15]^

![Structure of the Ara6 motif (as the methyl glycoside), which is present in both AG and LAM.](ar-2016-001647_0004){#fig4}

Although we could access many targets through donors such as **3**, the lack of generality of the method for synthesizing the β-Ara*f* glycosides was a limitation. Around the same time, the Crich group had demonstrated the influence of conformational restriction of the pyranose ring in the synthesis of β-mannopyranosides. In particular, it was shown that donors possessing a 4,6-*O*-benzylidene acetal (e.g., **11**, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A) could, under the proper conditions, produce β-mannopyranosides (**12**) with high stereoselectivity, whereas donors lacking this cyclic acetal (**13**) are unselective or even α-selective.^[@ref16],[@ref17]^ It was later demonstrated that the torsional restraints induced by the benzylidene acetal led to the in situ generation of an α-mannopyranosyl triflate (**15**, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B), which could then react with the alcohol in an S~N~2-like manner to produce the β-mannopyranoside. In the absence of this cyclic protecting group an ion-pair structure (e.g., **16**) is produced in place of **15**, which leads to increases in the amount of α-glycoside product.^[@ref18],[@ref19]^

![(A) Studies by Crich on the synthesis of β-mannopyranosides, showing the β-selective glycosyl triflate intermediate (**15**) and an α-selective/unselective intermediate (**16**).^[@ref19]^ (B) A conformationally restricted Ara*f*-thioglycoside (**17**).](ar-2016-001647_0005){#fig5}

These studies prompted us to consider an analogous approach for synthesis of β-Ara*f* linkages. The obvious extension would be to prepare a benzylidene acetal such as **17** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). However, we were aware that the yield of compounds of this type was generally low given the strain present in the *trans*-fused 5/6 ring system. These considerations were underway when, for other reasons, we prepared a series of 2,3-anhydro-furanoside thioglycosides (e.g., **18**, [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). Out of simple curiosity, the postdoctoral fellow carrying out this work, Raj Gadikota, tested how **18** behaved in glycosylation reactions. We were surprised to discover that it was indeed a highly stereoselective glycosyl donor, in most cases producing a single glycoside product. Even more surprising was that the product obtained was the one in which the glycosidic linkage was *cis* to the epoxide moiety, **19**.^[@ref20]^ We subsequently showed that the sulfoxide derivative **20** gave the same results when glycosylations were done under "Crich" conditions.^[@ref18],[@ref19]^ These results provided an alternative, albeit indirect, route to β-arabinofuranosides: glycosylation with donors such as **18a/18b**, followed by regioselective opening of the epoxide ring (**19**) with a nucleophile resulting in **20**.^[@ref21]^

![(A) 2,3-anhydrosugar donors **18a/18b** and their use in the synthesis of β-arabinofuranosides (**20**). (B) Postulated complex (**21**) formed in (−)-sparteine-mediated nucleophilic opening of O-5 deprotonated 2,3-anhydro-β-[d]{.smallcaps}-lyxofuranosides (e.g., **19**) by lithium alkoxides.](ar-2016-001647_0006){#fig6}

The opening of the epoxide in a regioselective manner proved to be more challenging than expected. Previous work^[@ref22]^ suggested that these substrates should be predisposed to nucleophilic attack at the desired C-3 position; however, with alkoxides as the nucleophile, the selectivities were modest.^[@ref21]^ Moreover, the substrates were quite robust. Heating at over 100 °C was necessary for reasonable rates to be achieved. A serendipitous discovery that lithium alkoxides provided better regioselectivity than their sodium or potassium counterparts led ultimately to a solution. We investigated the possibility that lithium binding additives might enhance the rate and regioselectivity of the reaction. After screening a number of such additives, graduate student Chris Callam found that both a rate enhancement and a substantial increase in regiocontrol could be obtained with (−)-sparteine. The temperature could be lowered to 70 °C, the reaction was complete in less than 30 min, and only the desired arabinofuranoside product was produced. While our initial thoughts were that the chirality of the additive was essential, that was shown not to be the case.^[@ref21]^ The reasons underlying this effect remain unclear, but the presence of a free OH group at C-5 in **19** (either present initially or liberated under the basic conditions of the reaction) is essential for good regiocontrol. Presumably, a ternary complex (e.g., **21**) between the lithium ion, the (−)-sparteine, and the substrate forms, which then directs the nucleophile to C-3. However, attempts to determine the structure of this intermediate have been unsuccessful.

Although we did not elucidate reasons for the high regioselectivity in the epoxide ring opening in glycosides of the type **19**, we did succeed in understanding the origins of the selectivity in the glycosylation reactions with 2,3-anhydro-furanoside sulfoxides.^[@ref23]^ Using experimental techniques pioneered by Crich,^[@ref18]^ coupled with ab initio calculations, we demonstrated that the origin of the high stereoselectivity was due to the formation of an intermediate α-glycosyl triflate that underwent an S~N~2-like nucleophilic displacement by the nucleophile. Thus, these reactions proceed in a way analogous to the Crich β-mannoside method,^[@ref19]^ with the epoxide serving as the conformational restraint.

The 2,3-anhydrosugar methodology could be applied to the preparation of complex arabinans, including the Ara6 motif (**10**, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), and it was also extended to hexofuranosides through the preparation of α-galactofuranosides by graduate student Yu Bai.^[@ref24],[@ref25]^ Nevertheless, the two step approach and the rather complex conditions required for the epoxide ring opening prompted us to explore other conformationally restricting groups that could achieve the same effect. Our initial focus was on groups that spanned O-2 and O-3 of the arabinofuranose ring, in particular **22** and **23** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). Unfortunately, we were never able to produce these compounds in yields sufficient for further studies. While engaged in these investigations, we were "scooped" by Boons^[@ref26]^ and soon after Ito.^[@ref27]^ Both groups reported that conformational restriction of the arabinofuranose ring through O-3/O-5, using silyl-based protecting groups, provided reagents (e.g., **24** and **25**) that were highly β-selective. The rationale for the selectivity builds from the "inside-attack" model proposed by Woerpel and co-workers to predict the stereoselectivity of nucleophilic attack onto five-membered ring oxacarbenium ions.^[@ref28]^ The silyl protecting group effectively locks the five-membered ring into an envelope conformation that is predisposed to attack leading to the β-glycoside.

![Conformationally restricted arabinofuranose donors (**22**--**25**, **27**) and an O-5 substituted β-arabinofuranoside motif present in mycobacterial LAM (**26**).](ar-2016-001647_0007){#fig7}

While regents such as **24** and **25** are very useful, and generally superior to 2,3-anhydrosugar donors, they have limitations with regard to the preparation of β-arabinofuranosides that are substituted on O-5. Such motifs (e.g., **26**) are present in mycobacterial LAM.^[@ref2]^ The use of O-3/O-5-protected reagents to prepare compounds of this type requires a number of transformations after introduction of the β-Ara*f* residue. To address this limitation, a postdoctoral fellow, Aki Imamura, explored the use of another class of donors possessing conformational restriction across O-2 and O-3: 2,3-*O*-xylylene-protected thioglycosides (e.g., **27**). Whereas our attempts to prepare **22** and **23** had failed, compounds of the general class **27** could be prepared straightforwardly. When explored in glycosylation reactions,^[@ref29]^ we were pleased to discover that these compounds, like **24** and **25**, are indeed generally β-selective, thus allowing straightforward access to compounds such as **26**. Following glycosylation, the O-5 protecting group can be cleaved, allowing further modification at that position.

The studies described above, as well as work carried out by others, have led to an arsenal of methods for the synthesis of essentially any mycobacterial arabinan fragment. Such syntheses can now be done with confidence and an increasingly diverse range of compounds have now been synthesized.^[@ref30]−[@ref37]^ Notable among these are large fragments of these molecules including species with more than 20 Ara*f* residues.^[@ref38]−[@ref40]^ Access to these compounds is now facilitating downstream biological/immunological investigations, including mapping of the epitopes of anti-LAM monoclonal antibodies,^[@ref41],[@ref42]^ the development of novel anti-TB vaccines,^[@ref37]^ and characterization of the specificity of the immune response that arises from LAM.

Synthesis of Mannopyranosides {#sec1.2}
=============================

A desire to carry-out structure--function studies of the biological role of LAM has led to interest in synthesizing fragments containing both Ara*f* and mannopyranose (Man*p*) residues.^[@ref31],[@ref37],[@ref43]−[@ref46]^ The Man*p* residues in LAM are α-(1→2)-, α-(1→6)-, and, in one strain, α-(1→3)-linked.^[@ref3]^ α-Man*p* residues in these linkages are found in a broad range glycoconjugates and are generally straightforward to prepare. In most cases, established approaches have led to the successful preparation of these molecules, although streamlined methods specific to these fragments have been reported.^[@ref47]^

Synthesis of Galactofuranosides {#sec1.3}
===============================

Several years after initiating the work on arabinofuranosides, we turned our attention to the other major furanose component in the mycobacterial cell wall: the galactan domain of the AG. Our interest was motivated by the identification of a galactofuranosyltransferase enzyme,^[@ref48]^ which, at the time, appeared to be the primary glycosyltransferase involved in galactan biosynthesis. Compared with the arabinan, the galactan is relatively simple. It is a linear chain of alternating β-(1→5) and β-(1→6)-linked Gal*f* residues, attached to a disaccharide containing rhamnose and *N*-acetylglucosamine.^[@ref2]^ Moreover, the linkages between the Gal*f* residues are 1,2-*trans*, and hence we envisioned that the assembly of galactan fragments would be straightforward through the use of donors with acyl protecting groups on O-2. We were aware of the pioneering work on galactofuranoside synthesis done by de Lederkremer, particularly the development and application of suitable donor and acceptor species, and our work was informed by those previous investigations.^[@ref49]−[@ref51]^

Although access to Gal*f* derivatives via a kinetically controlled Fischer glycosylation is possible,^[@ref52]^ significant amounts of pyranosides are often formed, which greatly complicates purification. For this reason, we generally access Gal*f* derivatives through the cyclization of the readily prepared galactose diethyl dithioacetal (**28**, [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). This method, which dates to the 1930s,^[@ref53]^ is robust, and through the use of iodine as a promoter,^[@ref54]^ we have used it to prepare both methyl and octyl galactofuranosides, **29** and **30**, respectively.^[@ref55]^ The former can be acylated and then converted into the corresponding thioglycoside (**31**) and in turn the trichloroacetimidate **32**. In continuation of this work, graduate student Gladys Completo then showed that **31** and **32** are useful donors for the preparation of β-Gal*f*-containing oligosaccharides (e.g., **33** and **34**, [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}), by both traditional and one-pot approaches.^[@ref55]^

![Access to the Galactofuranose Ring System from Dithioacetal **28** and Donors (**31** and **32**) Used in the Synthesis of β-Galactofuranosides](ar-2016-001647_0012){#sch2}

![Representative structures of synthetic β-galactofuranoside fragments of mycobacterial AG.](ar-2016-001647_0008){#fig8}

Using the general approaches outlined above, both we^[@ref55]^ and others^[@ref56],[@ref57]^ have synthesized a range of galactofuranosides. Such compounds have found significant application in studying mycobacterial galactan biosynthesis, in particular the two transferase enzymes involved in that process, GlfT1 and GlfT2.^[@ref58]^ Such studies have included kinetics studies of the enzyme,^[@ref59]^ the evaluation of active site probes,^[@ref60]−[@ref66]^ and X-ray crystallographic investigations.^[@ref67]^

Other Mycobacterial Cell Wall Glycans {#sec1.4}
=====================================

After developing approaches for the synthesis of the furanoside-containing glycans of the mycobacterial cell wall, we looked to another fascinating group of structures present in this complex assembly: the "extractable" glycolipids.^[@ref68]^ These species are found intercalated into the mycolic acid layer of the organism ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and often serve as modulators of the host immune system.^[@ref69]^ The extractable lipids can be grouped into four general classes: phenolic glycolipids (PGLs, e.g, **34**, [Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}),^[@ref69]^ glycopeptidolipids (GPLs, e.g., **35**),^[@ref70]^ trehalose mycolates (e.g., **36**), and lipooligosaccharides (LOSs, e.g., **37**).^[@ref5]^ These molecules are produced in a species specific manner. That is, not all mycobacterial strains synthesize all of the structures, and moreover, the molecules that are produced generally differ across species. Although the immunomodulatory properties of the extractable lipids are well established, detailed structure--function studies were not available when we began to consider synthesizing these compounds. We therefore set as a goal the synthesis of all known representatives of these glycolipids, both as the free glycan and as their lipidated (natural) forms. It was anticipated that access to such a library would greatly facilitate the development of a molecular-level appreciation of how these molecules interact with the immune system of the host.

![Representative structures of phenolic glycolipids (**34**), glycopeptidolipids (**35**), trehalose mycolates (**36**), and lipooligosaccharides (**37**).](ar-2016-001647_0009){#fig9}

On the surface, these molecules seem to be more straightforwardly accessible than the LAM and AG fragments described above. Indeed, while there is considerable prior art that could be used to develop synthetic routes to the extractable glycolipids, there are nevertheless challenges. One is the preparation of the unusual monosaccharides present in many of the targets (e.g., **37**). Another is the development of strategies that allow the introduction of fatty acyl acids, which effectively precludes the use of most ester protecting groups.

Mindful of these challenges, we first targeted what we considered to be the most tractable of the extractable glycolipids: PGLs. Although there is now a total synthesis of a complete PGL,^[@ref71]^ that paper had not appeared when we began our investigations. At the outset, to probe the effect of the glycan on cytokine function in the absence of the lipid domain, we targeted a family of all of the reported PGL structures, prepared as their *p*-methoxyphenyl glycosides (e.g., **38**, **39**, [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}).^[@ref72]−[@ref74]^ This work, done by a single graduate student, Hassan Elsaidi, was a significant undertaking. It was envisioned that the *p*-methoxyphenyl aglycone would serve as a suitable surrogate for the phenyl group of the native PGLs. Moreover, the presence of this group could facilitate the synthesis of more complex analogs, through its selective cleavage^[@ref75]^ and then coupling of the resulting oligosaccharide to other aglycones. In addition, strategies for the introduction of the methyl groups that characterize these species were investigated. In most cases it turned out to be more efficient to carry out methylation on the monosaccharide building blocks rather than on the more complex oligosaccharide products.

![Synthetic PGL analogs used to probe cytokine modulation.](ar-2016-001647_0010){#fig10}

After synthesizing the panel of more than 25 compounds, Hassan then evaluated their ability modulate the activity of proinflammatory cytokines (e.g., TNF-α) and nitric oxide. Although none of the compounds were inducers of these cytokines, many inhibited their production and these effects were structure dependent. Hassan went on to demonstrate that replacement of the aryl methoxy group with a longer, and yet still simple, lipid (**40**) enhanced this effect. Moreover, the potency of this compound approached that for phenolic glycolipid 1 (PGL-1) from *Mycobacterium leprae*, the only PGL available in usable quantities for purposes of comparison. Through these studies, we could conclude that the carbohydrate domain is essential for the ability of these molecules to inhibit the production of proinflammatory cytokines and that addition of a lipid domain enhances the effect, although the complex lipid present in the natural product appears not to be required for activity.

Conclusions and Future Directions {#sec2}
=================================

Through our studies of the last 20 years, we have systematically developed approaches for the chemical synthesis of mycobacterial cell wall glycans and then applied them to the preparation of a range of target molecules. The compounds we and others have made are increasingly being used in studies to probe the biosynthesis and biological function of the fascinating glycans produced by mycobacteria. Given the importance of tuberculosis as a global health threat, such studies will impact the development of novel drugs for treating mycobacterial disease, novel vaccines for preventing them, and new diagnostics. Current efforts in the group are focused on broadening our collection of extractable lipids structures, with a particular emphasis on the glycopeptidolipids and the lipooligosaccharides.^[@ref76]^
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